Business Update Neutral

2026-11-06 17:15

- USFDA inspected the formulations manufacturing facility of subsidiary Pinnacle Life Science Private Limited at Baddi, Himachal Pradesh from November 2 to November 6, 2026. - The inspection concluded with 3 observations in Form 483, with none related to Data Integrity. - There is no impact on financial, operational, or other activities of the company due to these observations.

Business Update Neutral

2026-11-04 19:39

- Audio recording of the Investor/Analyst conference call for Q2 & H1 FY27 financial results has been uploaded to the company's website. - Transcript of the conference call will be submitted to the stock exchanges and uploaded on the website in due course.

Financials Positive

2026-11-03 22:29

Q2 FY27 Consolidated Revenue ₹826.2Cr vs ₹652.8Cr (▲27% YoY) EBITDA ₹137.9Cr vs ₹84.4Cr (▲63% YoY) PAT ₹82.8Cr vs ₹45.2Cr (▲83% YoY) EBITDA Margin 16.6% vs 12.9% (▲370bps)

Business Update Positive

2026-11-03 22:17

- Q2 FY27 Consolidated Revenue grew 27% YoY to ₹828.8 Cr vs ₹652.9 Cr. - EBITDA jumped 63% YoY to ₹137.9 Cr with margins expanding 370 bps to 16.6%. - PAT surged 83% YoY to ₹82.8 Cr compared to ₹45.2 Cr. - Growth driven by API and Formulations demand alongside Sayakha facility scale-up.

Financials Positive

2026-11-03 19:12

Q2 FY27 Consolidated Revenue ₹826.24 Cr vs ₹652.79 Cr (▲26.6% YoY) EBITDA ₹135.36 Cr vs ₹84.28 Cr (▲60.6% YoY) PAT ₹82.77 Cr vs ₹45.16 Cr (▲83.3% YoY) EBITDA Margin 16.4% vs 12.9% (▲347bps)

Business Update Neutral

2026-10-28 19:38

Concall Schedule Concall Date: November 4, 2026 Concall Time: 11:00 AM IST

Business Update Positive

2026-10-08 19:24

- Crisil ESG Ratings & Analytic Limited assigned an ESG rating of 'Crisil ESG 61' (Strong) to Aarti Drugs Limited. - The rating is based on FY 2025-26 data available in the public domain. - The company did not engage Crisil for this rating and received the report on October 7, 2026.

Governance Neutral

2026-10-01 19:14

- Aarti Drugs Limited has updated the list of authorized persons under Regulation 30(5) of SEBI LODR Regulations, 2015, effective October 1, 2026. - Shri Adhish P. Patil (Managing Director) and Shri Harshit M. Savla (Jt. Managing Director) are authorized to determine materiality and make disclosures. - Shri Rushikesh V. Deole (Company Secretary) is authorized to make disclosures to the stock exchanges.

Governance Neutral

2026-09-30 19:51

- Shri Prakash M. Patil ceased to hold the positions of Chairman, Managing Director, and CEO due to early retirement effective September 30, 2026. - Shri Adhish P. Patil relinquished his position as Chief Financial Officer effective September 30, 2026, consequent to his promotion as Managing Director starting October 1, 2026.

Governance Neutral

2026-09-26 20:33

- Shareholders approved various changes in management at the 41st AGM held on September 26, 2026. - Shri Uday Moreshwar Patil ceased to be Whole-time Director upon retirement by rotation. - Shri Nilesh Bhalchandra Patil appointed as Whole-time Director effective September 26, 2026. - Shri Adhish Prakash Patil appointed as Managing Director effective October 01, 2026. - Re-appointments approved for key managerial personnel and independent directors.

Business Update Positive

2026-09-26 20:20

Aarti Drugs Limited shared its presentation made to shareholders at the 41st Annual General Meeting held on September 26, 2026. - Highlighted company history, growth milestones crossing ₹2,500 crores consolidated turnover, and global leadership in multiple API molecules. - Showcased diversified presence across APIs, Formulations, and Specialty Chemicals with manufacturing units and global export reach in 100+ countries. - Outlined strong R&D thrust with dedicated centers at Tarapur and Turbhe, focusing on complex generics, process development, and continuous innovation.

Business Update Positive

2026-09-02 22:03

- Submission of Business Responsibility and Sustainability Report for FY 2025-26. - Filed as per Regulation 34(2)(f) of SEBI (LODR) Regulations, 2015. - Details the company's ESG initiatives, policies, and performance. - The report is also available on the company's website.

Governance Positive

2026-08-27 12:47

- Board of Directors approved the "Aarti Drugs Limited Performance Stock Option Plan 2026" to grant up to 8,00,000 Performance Stock Options, convertible into equity shares of face value ₹10 each, subject to members' approval.

Governance Neutral

2026-08-24 22:01

- Board Meeting scheduled for Thursday, August 27, 2026. - Agenda includes consideration and approval of the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'. - Trading Window to remain closed from August 25, 2026, till August 29, 2026.

Business Update Neutral

2026-08-14 16:05

- Analyst / Institutional Investor Meetings Schedule - Meeting Date: 20th August 2026 - Meeting Time: 1:00 PM to 6:00 PM

Business Update Positive

2026-08-10 21:36

- Aarti Drugs Limited won a legal dispute against the GST Department. - The Hon'ble Supreme Court dismissed the GST Department's Special Leave Petition regarding a demand for IGST and penalty of ₹20.72 Crores. - The ruling is in the company's favor with no financial or operational impact.

Routine Neutral

2026-08-07 20:41

New Filing detected. See link for details.

Business Update Neutral

2026-08-04 17:53

- Concall Schedule - Concall Date: 10th August 2026 - Concall Time: 11:00 AM to 1:00 PM - Nature of Meeting: 1x1/ Group Meeting - Organised by: Nirmal Bang - Venue: Trident BKC, Mumbai

Business Update Neutral

2026-08-03 19:27

- Audio recording of the Investors/Analyst conference call on the Financial Results for the Quarter ended June 30, 2026, has been uploaded to the company's website. - The transcript for the call will be shared and uploaded in due course. - Link to recording: https://www.aartidrugs.com/reports-fillings-concall-recording

Financials Positive

2026-08-01 17:13

- Consolidated Revenue ₹703.6Cr vs ₹590.8Cr (▲19% YoY) - EBITDA ₹96.9Cr vs ₹74.4Cr (▲30% YoY) - PAT ₹50.1Cr vs ₹54.0Cr (▼7% YoY) - EBITDA Margin 13.8% vs 12.6% (▲120bps)

Business Update Positive

2026-08-01 16:35

CRITICAL RED FLAG DETECTED

- Gujarat Pollution Control Board (GPCB) revoked the closure direction for Aarti Drugs' Sayakha plant, allowing continued Amines manufacturing. - An interim Environmental Damage Compensation of ₹10,20,000 was paid for past non-compliances. - The company states no financial or operational impact.

Governance Positive

2026-07-31 22:12

- Leadership transition announced by Aarti Drugs Limited effective October 1, 2026. - Shri Prakash M. Patil to retire as Chairman, Managing Director & CEO effective September 30, 2026, and will continue to provide guidance. - Shri Rashesh C. Gogri elevated to Chairman in addition to his existing role as Managing Director. - Shri Adhish P. Patil appointed as Managing Director (subject to shareholder approval). - The changes are aimed at strengthening governance and ensuring long-term strategic growth.

Governance Neutral

2026-07-31 20:14

CRITICAL RED FLAG DETECTED

- Chairman, MD & CEO Shri Prakash M. Patil retires Sept 30, 2026 for orderly leadership transition. - Shri Rashesh C. Gogri elevated to Chairman (retains MD), and Shri Adhish P. Patil (CFO) appointed new MD, both effective Oct 1, 2026. - Shri Nilesh B. Patil appointed Whole-time Director; other directors re-appointed. - Board committees reconstituted to reflect changes.

Financials Positive

2026-07-31 19:22

- Consolidated Revenue ₹702.78 Cr vs ₹590.51 Cr (▲19.0% YoY) - EBITDA ₹96.11 Cr vs ₹74.08 Cr (▲29.7% YoY) - PAT ₹50.13 Cr vs ₹53.97 Cr (▼7.1% YoY) - EBITDA Margin 13.7% vs 12.5% (▲113bps)

AARTIDRUGS

Aarti Drugs Limited

Price Chart

Filing History

Unlock Full History